ArticleFrontiers in pharmacology2025
Qishen Yiqi alleviates periostin-mediated cardiac fibrosis and hypertrophy in Dahl hypertensive rat hearts and angiotensin II-induced cardiac organoids.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cardiac organoids in toxicology: from construction strategies and research trends to precision screening applications.Stem cell research & therapy · 2026Review
- Application and prospect of breast cancer organoids model in the field of traditional Chinese medicine and natural compounds.Journal of translational medicine · 2026Review
- Senkyunolide I and Danshensu in combination ameliorate post-MI myocardial fibrosis by regulatingFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Arterial hypertension is a significant risk factor for cardiovascular health. Long-lasting hypertension leads to damage to multiple organs, such as the heart, kidneys, and vascular bed damage. We have previously shown that a component-based Chinese medicine Qishen Yiqi (QSYQ) lowered the blood pressure and ameliorated kidney damage in salt-sensitive hypertensive rats. However, its effect on the hypertensive rat heart remains unknown. This study aims to explore the efficacy and mechanism of QSYQ in hypertensive heart disease. Methods: Dahl salt-sensitive hypertension rats were fed with normal or high-salt diets with gavage administration of QSYQ or control drug for 9 weeks. Cardiac ultrasound, tissue pathology and transcriptome analysis were performed on the hypertensive heart Results: QSYQ prevented the development of diastolic dysfunction of LVPW and E/A and reduced fibrosis and hypertrophy in the hypertensive rat hearts. In cardiac spheroids, angiotensin II induced an exacerbated hypertrophic morphology, fibrotic pathology, and elevated collagen expression. QSYQ treatment effectively reversed these abnormalities. Transcriptome analysis revealed that periostin is a key target of QSYQ in the hypertensive heart. Consistently, QSYQ also significantly downregulated the expression of periostin and fibrosis indicators such as TGF-β, Conclusion: QSYQ alleviates cardiac fibrosis and hypertrophy in Dahl Salt-sensitive hypertension rats
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.